NASDAQ
HROW

Harrow Health Inc

Drug Manufacturers-Specialty & Generic
Healthcare

Prices are adjusted according to historical splits.

Harrow Health Inc Stock Price

Vitals

Today's Low:
$16.2301
Today's High:
$16.815
Open Price:
$16.49
52W Low:
$7.51
52W High:
$28.25
Prev. Close:
$16.61
Volume:
430986

Company Statistics

Market Cap.:
$543.94 million
Book Value:
0.74
Revenue TTM:
$102.73 million
Operating Margin TTM:
1.64%
Gross Profit TTM:
$63.21 million
Profit Margin:
-15.85%
Return on Assets TTM:
0.66%
Return on Equity TTM:
-118.64%

Company Profile

Harrow Health Inc had its IPO on 2007-09-28 under the ticker symbol HROW.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Harrow Health Inc has a staff strength of 217 employees.

Stock update

Shares of Harrow Health Inc opened at $16.49 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $16.23 - $16.82, and closed at $16.46.

This is a -0.9% slip from the previous day's closing price.

A total volume of 430,986 shares were traded at the close of the day’s session.

In the last one week, shares of Harrow Health Inc have increased by +6.26%.

Harrow Health Inc's Key Ratios

Harrow Health Inc has a market cap of $543.94 million, indicating a price to book ratio of 287.6519 and a price to sales ratio of 4.0786.

In the last 12-months Harrow Health Inc’s revenue was $102.73 million with a gross profit of $63.21 million and an EBITDA of $8.47 million. The EBITDA ratio measures Harrow Health Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Harrow Health Inc’s operating margin was 1.64% while its return on assets stood at 0.66% with a return of equity of -118.64%.

In Q2, Harrow Health Inc’s quarterly earnings growth was a negative -64% while revenue growth was a positive 43.5%.

Harrow Health Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.55 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Harrow Health Inc’s profitability.

Harrow Health Inc stock is trading at a EV to sales ratio of 4.312 and a EV to EBITDA ratio of 148.8733. Its price to sales ratio in the trailing 12-months stood at 4.0786.

Harrow Health Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$223.99 million
Total Liabilities
$23.01 million
Operating Cash Flow
$-1249000.00
Capital Expenditure
$1.25 million
Dividend Payout Ratio
0%

Harrow Health Inc ended 2024 with $223.99 million in total assets and $0 in total liabilities. Its intangible assets were valued at $223.99 million while shareholder equity stood at $22.05 million.

Harrow Health Inc ended 2024 with $0 in deferred long-term liabilities, $23.01 million in other current liabilities, 30000.00 in common stock, $-120365000.00 in retained earnings and $332000.00 in goodwill. Its cash balance stood at $22.75 million and cash and short-term investments were $22.75 million. The company’s total short-term debt was $764,000 while long-term debt stood at $169.71 million.

Harrow Health Inc’s total current assets stands at $60.30 million while long-term investments were $0 and short-term investments were $6.92 million. Its net receivables were $18.26 million compared to accounts payable of $10.51 million and inventory worth $8.56 million.

In 2024, Harrow Health Inc's operating cash flow was $-1249000.00 while its capital expenditure stood at $1.25 million.

Comparatively, Harrow Health Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$16.46
52-Week High
$28.25
52-Week Low
$7.51
Analyst Target Price
$38.8

Harrow Health Inc stock is currently trading at $16.46 per share. It touched a 52-week high of $28.25 and a 52-week low of $28.25. Analysts tracking the stock have a 12-month average target price of $38.8.

Its 50-day moving average was $18.23 and 200-day moving average was $18.28 The short ratio stood at 5.66 indicating a short percent outstanding of 0%.

Around 627% of the company’s stock are held by insiders while 6532.2% are held by institutions.

Frequently Asked Questions About Harrow Health Inc

The stock symbol (also called stock or share ticker) of Harrow Health Inc is HROW

The IPO of Harrow Health Inc took place on 2007-09-28

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
Chg
Chg%
$252.75
-23.15
-8.39%
$161.25
3.3
+2.09%
$4.5
-0.12
-2.6%
$42.5
0.26
+0.62%
$105.7
-8.3
-7.28%
$6.7
-0.02
-0.3%
$2.58
0.12
+4.88%
$343.65
-5.65
-1.62%
AAM-P-A (AAM-P-A)
$25
0
0%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Harrow Health, Inc., an eyecare pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies. The company offers ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic medicines, including IOPIDINE and MOXEZA; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection drug candidate. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

Address

102 Woodmont Boulevard, Nashville, TN, United States, 37205